Johnson & Johnson will reportedly seek clearance for a booster vaccine this week as concerns mount regarding the effectiveness of its single-shot COVID-19 vaccine compared to other injections.
The New York Times, citing unidentified officials familiar with the company’s plans, reported Monday that Johnson & Johnson plans to apply for clearance from the Food and Drug Administration (FDA) earlier this week for a booster injection, joining Pfizer- BioNTech and Moderna to request approval for an additional shot.
The FDA announced Friday that its expert advisory committee will discuss booster shots for Johnson & Johnson’s vaccine during their Oct. 4 meetings. 14 and 15.
The agency will also discuss booster shots for the Modern COVID-19 vaccine during those meetings.
FDA’s scheduling of an advisory committee meeting even before Johnson & Johnson submitted a request for authorization of its booster vaccine reflects the urgency in which the federal health agency seeks to obtain approval for additional doses of vaccines. to better protect Americans, the Times noted.
Last month, the health agency authorized booster shots for Pfizer-BioNTech’s COVID-19 vaccine for people 65 and older and others at high risk for serious illness.
Moderna announced in early September that it began submitting data about its booster vaccine to the FDA.
While all three vaccines currently licensed in the U.S. have been shown to be effective in protecting against serious diseases, one study from the Centers for Disease Control and Prevention published late last month found that J & J’s vaccine was 71 percent effective in preventing COVID-19 hospitalizations, while Pfizer’s injections were 88 percent effective and injections of Moderna were 93 percent effective.
A Johnson & Johnson spokesperson on Monday referred The Hill to a company announcement in September that said research showed its booster provides 94 percent COVID-19 protection.
– Updated at 7:42 am